Mitochondria as a target for neurotoxins and neuroprotective agents - Wikidata - wikimedia - TriplyDB

Mitochondria as a target for neurotoxins and neuroprotective agents

Mitochondria as a target for neurotoxins and neuroprotective agents

http://www.wikidata.org/entity/Q28186231

about

sameAs

Evaluation of Dimebon in cellular model of Huntington's disease Translatability scoring in drug development: eight case studies Latrepirdine for Alzheimer's disease Dimebon for Alzheimer's disease Novel therapeutics for Alzheimer's disease: an update Discovery of a proneurogenic, neuroprotective chemical Local melatoninergic system as the protector of skin integrity Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention Serotonin-kynurenine hypothesis of depression: historical overview and recent developments Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam Ultrasensitive label-free photothermal imaging, spectral identification, and quantification of cytochrome c in mitochondria, live cells, and solutions.Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis.Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide Mitochondrial Drugs for Alzheimer Disease.Current treatment and recent clinical research in Alzheimer's disease The rise and fall of Dimebon.Drug development for Alzheimer's disease: where are we now and where are we headed?Development of proneurogenic, neuroprotective small molecules.Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.Frontiers in Alzheimer's disease therapeutics.Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies.The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys Drug development for Alzheimer's disease: recent progress Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice.N-acetylserotonin and aging-associated cognitive impairment and depression.NMDA receptors in clinical neurology: excitatory times ahead.Huntington's disease: progress and potential in the field.Potential Role of Caffeine in the Treatment of Parkinson's Disease.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability.The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.Mitochondrial structural and functional dynamics in Huntington's disease.

P2860

Q21202838-4B7BFF84-3F4B-4B60-842C-8B582C14ED66 Q22241760-D05C00D7-5E21-48CF-BD5A-86D24EF989C7 Q24186444-8BA24077-6644-4C17-8727-F9279F3298D9 Q24234998-15DA2EBA-E48B-4F33-BF1E-831BFB69CE00 Q24620383-BDBFF08A-2D1F-45E9-95DF-1246DB7B6584 Q24620801-B4DD4076-E997-453E-8106-82BEFDA11E01 Q26828985-86EBFA69-48CF-4837-B8DC-CF32E532D65D Q26829899-6CAD6512-B0BB-4010-9A45-BA71511FAD9F Q26859141-C3AD5364-E1FB-4104-B4E0-A05AC5C17668 Q26865358-7D0D5BF0-647F-4738-840A-2963C0D0101F Q27012779-279587F1-3F74-4003-8253-E5E56E067937 Q27338799-72C3FD97-7FC2-4F82-A4C5-85E1E80BF459 Q27500402-14CA69B9-4B2F-4DD5-992C-6D7938C07B1F Q28384303-0A13CB2B-5B20-40BB-B585-EA956BC81BBC Q30525846-27BF2DB2-F871-437B-94AF-75727FB142A7 Q30525849-4F463A45-B205-4CE5-9F78-3BE8AFF9908E Q33592247-39A60A78-EE50-44EB-9982-88C1F530139A Q33870388-7A0945F9-6C15-44EB-B919-DDC2568997C5 Q34016406-6B68133D-7348-452A-B676-DF3CF40559A0 Q34067487-E2F87749-1F1A-419F-A62E-2BE37D40A6F6 Q34146766-43D1D0E3-FA3D-448D-8C7E-45FFC9FE9580 Q34166256-77AEA2E8-D9E2-4F5C-8942-B5ED3EB10C40 Q34551056-90A5F0CF-A636-4C8E-9A98-DBE7D814A7B8 Q34557710-038AF643-BB1F-44D1-A6EA-7DF0F7B370C3 Q34994270-08DB092F-DB3B-4847-A79E-40FF644E6FE2 Q35086876-B4F11338-1925-4499-80F6-31230876862B Q35140660-3F04D1DC-3A06-43EE-A3F9-6363FB347F57 Q35376045-AFBDACA3-2257-4742-8C19-C093750FC15F Q35545974-DDB30D27-8701-4DEB-B9ED-90F42FE4506D Q35957568-BBD59B7B-2AF9-4C9F-8938-BEDCD6482B37 Q35958359-8A1B4187-80A0-4FD4-84D7-0A951DE4A459 Q36304050-1B02F671-CBD3-4ED3-BB4A-3B44D7BEDD9B Q36409066-650A0A4A-B009-4AAC-9C8D-72940E091922 Q36660216-CE76B03D-5742-422A-B2A3-8A6F8A2FE72E Q37016096-C06DD6AC-7BCA-4126-8E27-2FC3754D7F22 Q37129378-80EC056B-7061-4EC3-BCA7-549F85768467 Q37198579-980ADDBC-2176-42B8-A8F8-697694714045 Q37281161-C640E164-7385-4E1F-8B30-81468E2308B5 Q37334202-CD9E2F9F-9B60-4EF1-8944-CAC431B8BA17 Q37356257-2CA14E75-0E92-42DA-9D40-DEB86F8CF3C9

P2860

Mitochondria as a target for neurotoxins and neuroprotective agents

http://www.wikidata.org/entity/Q28186231

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Mitochondria as a target for neurotoxins and neuroprotective agents

@ast

Mitochondria as a target for neurotoxins and neuroprotective agents

@en

Mitochondria as a target for neurotoxins and neuroprotective agents

@nl

type

label

Mitochondria as a target for neurotoxins and neuroprotective agents

@ast

Mitochondria as a target for neurotoxins and neuroprotective agents

@en

Mitochondria as a target for neurotoxins and neuroprotective agents

@nl

altLabel

Mitochondria as a Target for Neurotoxins and Neuroprotective Agents

@en

prefLabel

Mitochondria as a target for neurotoxins and neuroprotective agents

@ast

Mitochondria as a target for neurotoxins and neuroprotective agents

@en

Mitochondria as a target for neurotoxins and neuroprotective agents

@nl

P1433

Q28186231-F3C745E6-C742-48B8-B296-C0A2A215F25C

P1476

Q28186231-14936CB2-BF14-4666-ADA5-9D29BE8D865B

Q28186231-39750304-F84F-4901-81E4-5A1594467F28

P2093

Q28186231-04E104F8-D5A8-48E7-A888-579947B67A67

Q28186231-12542EA2-116A-4845-8A80-1E28EB69A1EA

Q28186231-165FA72A-5F60-4ED9-B15E-58BD54B3CE41

Q28186231-3C224DF1-396C-4775-860B-54189CD461A4

Q28186231-424B33E7-6768-4D14-AFC7-E3C440BE5EA9

Q28186231-73D55CDB-BDF2-4FA7-9689-C28520E8AD56

Q28186231-9E6C1C76-B1F9-410C-B8D2-0159E25E0978

Q28186231-B7640A2E-97BD-44B5-8311-D42BF3C21FD9

Q28186231-D0807384-C2CB-4654-B2B6-B122FDF8572F

Q28186231-EDA60437-75EC-466A-8F62-0B123B637EF1

P2860

Q28186231-125170A8-A2CE-4BEF-933F-3495E209F8E1

P304

Q28186231-AFFAD54E-928A-4510-81DF-0B31DEA77E84

Q28186231-C3979AF7-AABC-426E-AD3B-30D4F7817E81

P31

Q28186231-E5EC080C-03C9-4190-A6CB-C4DD36632924

P3181

Q28186231-DC5CEEB4-2395-4F9A-8E87-CD90F1524591

P356

Q28186231-9D5C2E01-D48D-4743-BBE9-15CA3ED50071

P407

Q28186231-04B16D6F-C989-4837-A7D0-40C1D9E18EDC

P433

Q28186231-10C73F4E-DBC2-4E46-BD2E-E62394CEDA59

P478

Q28186231-3D53F8E6-A48C-48D2-8FE8-93F49944635F

P577

Q28186231-1A5DA18E-40DF-4F83-9389-AC6600339343

P5875

Q28186231-77FC6785-9655-4FDD-B816-2A316DCD28D9

P698

Q28186231-A0F260B2-1CC7-42B3-877C-75DEC09F59D6

P921

Q28186231-88870261-58E9-4B11-A9C1-065A4297FFF7

P3181

P356

J.1749-6632.2003.TB07541.X

P1433

Annals of the New York Academy of Sciences

P1476

Mitochondria as a Target for Neurotoxins and Neuroprotective Agents

@en

Mitochondria as a target for neurotoxins and neuroprotective agents

@en

P2093

ELENA G. KIREEVA

http://www.w3.org/2001/XMLSchema#string

ELENA P. SHEVTSOVA

http://www.w3.org/2001/XMLSchema#string

Elena G Kireeva

http://www.w3.org/2001/XMLSchema#string

Elena P Shevtsova

http://www.w3.org/2001/XMLSchema#string

GREGORY F. OXENKRUG

http://www.w3.org/2001/XMLSchema#string

Gregory F Oxenkrug

http://www.w3.org/2001/XMLSchema#string

SERGEY O. BACHURIN

http://www.w3.org/2001/XMLSchema#string

SERGEY O. SABLIN

http://www.w3.org/2001/XMLSchema#string

Sergey O Bachurin

http://www.w3.org/2001/XMLSchema#string

Sergey O Sablin

http://www.w3.org/2001/XMLSchema#string

P2860

The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism.

P304

334-344

http://www.w3.org/2001/XMLSchema#string

334-44; discussion 345-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4384634

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1749-6632.2003.TB07541.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

993

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10668996

http://www.w3.org/2001/XMLSchema#string

P698

12853325

http://www.w3.org/2001/XMLSchema#string

P921